High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity

Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here, we isolated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynn, Rachel C, Feng, Yang, Schutsky, Keith, Poussin, Mathilde, Kalota, Anna, Dimitrov, Dimiter S, Powell, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889499/
https://www.ncbi.nlm.nih.gov/pubmed/26898190
http://dx.doi.org/10.1038/leu.2016.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889499/
https://www.ncbi.nlm.nih.gov/pubmed/26898190
http://dx.doi.org/10.1038/leu.2016.35

Ejemplares similares